Jeff C Alexander

US Patent:

20110123564, May 26, 2011

Filed:

Jul 30, 2010

Appl. No.:

12/847767

Inventors:

Timothy P. MAYALL - Encinitas CA, US
Jeff ALEXANDER - San Diego CA, US

Assignee:

PAXVAX, INC. - San Diego CA

International Classification:

A61K 39/235
A61K 39/07
A61K 39/112
A61K 39/04
A61K 39/015
A61P 31/04
A61P 31/12
A61P 31/16
A61P 31/18

US Classification:

4241991

Abstract:

The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.

US Patent:

20170367543, Dec 28, 2017

Filed:

Jun 27, 2016

Appl. No.:

15/193570

Inventors:

- Paris, FR
Ryan RUTLEDGE - Lynnwood WA, US
Jeff ALEXANDER - North Bend WA, US

Assignee:

L'OREAL - Paris

International Classification:

A47K 7/04
A46B 15/00
B08B 1/00

Abstract:

A personal care appliance is provided that includes a brushhead for use in skincare; an appliance body having a motor assembly for oscillating the brushhead, wherein the brushhead or a portion of the motor assembly that is configured to oscillate includes a marking; and a brush encoder configured to detect the marking, and determine the oscillation of the brushhead.

US Patent:

20150086579, Mar 26, 2015

Filed:

Sep 5, 2014

Appl. No.:

14/478991

Inventors:

- San Diego CA, US
Jeff ALEXANDER - San Diego CA, US

International Classification:

C12N 15/86
C12N 7/00
A61K 39/145

US Classification:

4241861, 4242331

Abstract:

The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.